Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment

Clinical Endocrinology

Volumn 71, Issue 5, 2009, Pages 652-658

  Glintborg, Dorte ^a   Andersen, Marianne ^a   Richelsen, Bjørn ^b   Bruun, Jens M ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; INSULIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLACEBO; TESTOSTERONE;

ARTICLE; BIVARIATE ANALYSIS; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GEOMETRY; HIRSUTISM; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPOSITY; CHEMOKINE CCL2; CHEMOKINE CCL3; CHOLESTEROL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INTRAMOLECULAR OXIDOREDUCTASES; LIPOPROTEINS, HDL; MACROPHAGE MIGRATION-INHIBITORY FACTORS; POLYCYSTIC OVARY SYNDROME; RADIOIMMUNOASSAY; TESTOSTERONE; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 70349696503     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03523.x     Document Type: Article

References (50)

1. Barth, J.H. (1997) Investigations in the assessment and management of patients with hirsutism. Current Opinion in Obstetrics and Gynecology, 9, 187 192.
2. Erkkola, R. Ruutiainen, K. (1990) Hirsutism: definitions and etiology. Annals of Medicine, 22, 99 103.
3. Rittmaster, R.S. (1997) Hirsutism. Lancet, 349, 191 195.
4. Glintborg, D., Henriksen, J.E., Andersen, M. et al 2004) The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian, premenopausal women with hirsutism as the referral diagnosis. Fertility and Sterility, 82, 1570 1579.
5. Azziz, R., Sanchez, L.A., Knochenhauer, E.S. et al 2004) Androgen excess in women: experience with over 1000 consecutive patients. Journal of Clinical Endocrinology and Metabolism, 89, 453 462.
6. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome 2004) Fertility and Sterility, 81, 19 25.
7. Salley, K.E., Wickham, E.P., Cheang, K.I. et al 2007) Position Statement: glucose intolerance in polycystic ovary syndrome a position statement of the androgen excess society. Journal of Clinical Endocrinology and Metabolism, 92, 4546 4556.
8. Douchi, T., Ijuin, H., Nakamura, S. et al 1995) Body fat distribution in women with polycystic ovary syndrome. Obstetrics and Gynecology, 86, 516 519.
9. Kirchengast, S. Huber, J. (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Human Reproduction, 16, 1255 1260.
10. Despres, J.P. Lemieux, I. (2006) Abdominal obesity and metabolic syndrome. Nature, 444, 881 887.
11. Dandona, P., Aljada, A., Ghanim, H. et al 2004) Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. Journal of Clinical Endocrinology and Metabolism, 89, 5043 5047.
12. Fasshauer, M. Paschke, R. (2003) Regulation of adipocytokines and insulin resistance. Diabetologia, 46, 1594 1603.
13. Fain, J.N., Tichansky, D.S. Madan, A.K. (2006) Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism, 55, 1113 1121.
14. Weisberg, S.P., McCann, D., Desai, M. et al 2003) Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation, 112, 1796 1808.
15. Bruun, J.M., Lihn, A.S., Pedersen, S.B. et al 2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. Journal of Clinical Endocrinology and Metabolism, 90, 2282 2289.
16. Cancello, R., Henegar, C., Viguerie, N. et al 2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes, 54, 2277 2286.
17. Church, T.S., Willis, M.S., Priest, E.L. et al 2005) Obesity, macrophage migration inhibitory factor, and weight loss. International Journal of Obesity, 29, 675 681.
18. Christiansen, T., Richelsen, B. Bruun, J.M. (2005) Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. International Journal of Obesity, 29, 146 150.
19. Westerbacka, J., Kolak, M., Kiviluoto, T. et al 2007) Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes, 56, 2759 2765.
20. Sell, H. Eckel, J. (2007) Monocyte chemotactic protein-1 and its role in insulin resistance. Current Opinion in Lipidology, 18, 258 262.
21. Herder, C., Klopp, N., Baumert, J. et al 2008) Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Diabetologia, 51, 276 284.
22. Glintborg, D., Frystyk, J., Hojlund, K. et al 2008) Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clinical Endocrinology, 68, 165 174.
23. Glintborg, D., Andersen, M., Hagen, C. et al 2006) Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. European Journal of Endocrinology, 155, 337 345.
24. Hu, W.H., Qiao, J. Li, M.Z. (2007) [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases]. Zhonghua Yi Xue Za Zhi, 87, 721 724.
25. Hu, W.H., Qiao, J., Zhao, S.Y. et al 2006) [Monocyte chemoattractant protein-1 and its correlation with lipoprotein inpolycystic ovary syndrome]. Beijing Da Xue Xue Bao. Yi Xue Ban, 38, 487 491.
26. Lord, J.M., Flight, I.H. Norman, R.J. (2003) Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 3, CD003053.
27. Mayerson, A.B., Hundal, R.S., Dufour, S. et al 2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes, 51, 797 802.
28. Miyazaki, Y., Mahankali, A., Matsuda, M. et al 2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 87, 2784 2791.
29. Mohanty, P., Aljada, A., Ghanim, H. et al 2004) Evidence for a potent antiinflammatory effect of rosiglitazone. Journal of Clinical Endocrinology and Metabolism, 89, 2728 2735.
30. Glintborg, D., Andersen, M., Hagen, C. et al 2005) Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clinical Endocrinology, 62, 683 691.
31. Glintborg, D., Stoving, R.K., Hagen, C. et al 2005) Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 5605 5612.
32. Glintborg, D., Hermann, A.P., Andersen, M. et al 2006) Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility, 86, 385 397.
33. Rosenfield, R.L. (2005) Clinical practice. Hirsutism. New England Journal of Medicine, 353, 2578 2588.
34. Lykkesfeldt, G., Bennett, P., Lykkesfeldt, A.E. et al 1985) Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clinical Endocrinology, 23, 385 393.
35. Altman, D.G. (1991) Comparing groups - continuous data. Practical Statistics for Medical Research. 1st edn, pp. 199 202. Chapman and Hall, London.
36. Herder, C., Kolb, H., Koenig, W. et al 2006) Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care, 29, 368 371. (Pubitemid 44106520)
37. Harman-Boehm, I., Bluher, M., Redel, H. et al 2007) Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. Journal of Clinical Endocrinology and Metabolism, 92, 2240 2247.
38. Bjorntorp, P. (1996) The android woman - a risky condition. Journal of Internal Medicine, 239, 105 110.
39. Bornstein, S.R., Rutkowski, H. Vrezas, I. (2004) Cytokines and steroidogenesis. Molecular and Cellular Endocrinology, 215, 135 141.
40. Aloisi, A.M., Pari, G., Ceccarelli, I. et al 2005) Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF). Pain, 115, 142 151.
41. Christodoulakos, G.E., Lambrinoudaki, I.V., Economou, E.V. et al 2007) Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. Atherosclerosis, 193, 142 150.
42. Banaszewska, B., Pawelczyk, L., Spaczynski, R.Z. et al 2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism, 92, 456 461.
43. Izquierdo, D., Foyouzi, N., Kwintkiewicz, J. et al 2004) Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertility and Sterility, 82, 1193 1197.
44. Morin-Papunen, L., Rautio, K., Ruokonen, A. et al 2003) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 4649 4654.
45. Ibanez, L. de Zegher, F. (2004) Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. Journal of Clinical Endocrinology and Metabolism, 89, 1592 1597.
46. Mueck, A.O., Seeger, H. Wallwiener, D. (2002) Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause, 9, 273 281.
47. Ibanez, L., Jaramillo, A.M., Ferrer, A. et al 2005) High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Human Reproduction, 20, 2457 2462.
48. Sell, H., Etze-Schroeder, D., Eckardt, K. et al 2006) Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochemical and Biophysical Research Communications, 343, 700 706.
49. Sartipy, P. Loskutoff, D.J. (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proceedings of the National Academy of Sciences USA, 100, 7265 7270.
50. Chacon, M.R., Fernandez-Real, J.M. Richart, C. et al 2007) Monocyte chemoattractant protein-1 in obesity and type 2 diabetes. Insulin sensitivity study. Obesity (Silver Spring), 15, 664 672.